Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
John M
JM
Kirkwood
Ahmad A
AA
Tarhini
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D005353:Fibronectins / Q000097:blood; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008545:Melanoma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D018579:Patient Selection; D011237:Predictive Value of Tests; D040901:Proteomics; D011994:Recombinant Proteins / Q000627:therapeutic use; D015203:Reproducibility of Results; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013997:Time Factors; D017211:Treatment Failure; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005353:Fibronectins; C508594:IL2 protein, human; D007376:Interleukin-2; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A